>>> US Gapping up


Zapping up
In reaction to earnings/guidance:

  • FDX +2.4%

Other news:

  • BALY +6% (announces modified "Dutch auction" tender offer to purchase shares at $19.25-$22)
  • FERG +3.4% (enters entered into a non-discretionary arrangement with its brokers J.P. Morgan Securities in continuation of its $2 billion share repurchase program)
  • BHC +3.3% (chairman resigns)
  • SNY +3.2% (Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine)
  • NRDS +3.2% (to acquire On The Barrelhead for $120 mln)
  • EBS +3.1% (receives FDA Acceptance of BLA for AV7909 Anthrax vaccine candidate)
  • NTLA +2.4% (Intellia Therapeutics and Regeneron Pharmaceuticals (REGN) announce additional "positive" interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate NTLA-2001)
  • BMRN +2.3% (confirms that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization for its investigational gene therapy valoctocogene roxaparvovec for adults with severe hemophilia A)
  • CSTL +2.2% (announces study findings that evaluated DecisionDx-UM)
  • BCS +2.2% (acquires Kensington Mortgage Company)
  • TAK +1.9% (to succeed to the rights and obligations relating to Plasma-Derived Therapies and all other businesses of Nihon through an absorption-type company split)
  • NVS +1.8% (receives positive CHMP opinion for Scemblix a novel treatment for adult patients with chronic myeloid leukemia)
  • RKLB +1.7% (prepares to launch CAPSTONE to the Moon)
  • DDOG +1.6% (launches Datadog Audit Trail)
  • PRIM +1.6% (receives $260 mln solar project award)
  • GSK +1.1% (Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine)
  • PBR +1.1% (approved the sale of its total stake in the maritime concessions groups named Golfinho Cluster and Camarupim Cluster)

Analyst comments:

  • ACB +4.2% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
  • BDX +1.2% (upgraded to Overweight from Equal Weight at Wells Fargo)